Vidofludimus hemicalcium
Based on 4 publication(s) in Google Scholar
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR.
For research use only. We do not sell to patients.
- CAS No.: 1354012-90-0
- Formula: C20H18FNO4.1/2Ca
- Molecular Weight:375.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Vidofludimus hemicalcium
More
Biological Activity
Vidofludimus hemicalcium (0-1 µM) selectively activats FXR in a concentration dependent manner with an EC50 value of about 450 nM in inducing the recruitment of various coactivator LXXLL motifs[1].
Vidofludimus hemicalcium (0-8 μM) blocks nuclear translocation of p65 by suppressing IKK-IκB-NF-κB pathway[1].
Vidofludimus hemicalcium has inhibitory activity for human DHODH with an IC50 value of 160 nM[2].
Vidofludimus hemicalcium inhibits dihydro-orotate dehydrogenase and lymphocyte proliferation in vitro[3].
Vidofludimus hemicalcium inhibits interleukin (IL)-17 secretion in vitro independently of effects on lymphocyte proliferation[3].
Vidofludimus hemicalcium completely blocks IL-23 + IL-1β-stimulated secretion of IL-17 by colonic strips in ex vivo[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Vidofludimus hemicalcium (p.o; 60 mg/kg; for 6 days) effectively improves many parameters of TNBS-induced colitis in rats and has inhibitory effects on colonic STAT3 and IL-17[3]."
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1354012-90-0
-
Molecular Weight 375.40
-
Formula C20H18FNO4.1/2Ca
-
SMILES
O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O.[Ca].[1/2]
-
Synonyms
4sc-101 hemicalcium; SC12267 hemicalcium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
J Med Virol
Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus. [Abstract]2024 Jan;96(1):e29372. PMID: 38235544 -
ChemMedChem
Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity. [Abstract]2024 Oct 1;19(19):e202400292. PMID: 38887198 -
-
Purity & Documentation
References
[1]. Yanlin Zhu, et al. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Front Pharmacol. 2020 May 14;11:590. [Content Brief]
[2]. Andreas Muehler, et al. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102129. [Content Brief]
[3]. Leo R Fitzpatrick, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vidofludimus hemicalcium Related Classifications
HY-14908A Related Classifications
Powered by Bioz
- Vidofludimus hemicalcium
- 1354012-90-0
- 4sc-101 hemicalcium
- SC12267 hemicalcium
- Dihydroorotate Dehydrogenase
- Interleukin Related
- FXR
- oral
- non-alcoholic fatty liver disease (NAFLD)
- dihydroorotate dehydrogenase (DHODH)
- farnesoid X receptor (FXR)
- immunomodulatory
- inflammatory bowel disease (IBD)
- fatty liver
- Inhibitor
- inhibitor
- inhibit